HIK.L
HIK.L
GB00B0LCW083
HIKMA PHARMACEUTICALS PLC ORD S
Loading chart...

Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Related stocks

KNSA
KNSA • United Kingdom
Kiniksa Pharmaceuticals Interna
79.78 USD
6.14B USD 1Y +105.6%
SFZN.SW
SFZN.SW • Switzerland
SIEGFRIED N
67.5 CHF
3.56B USD 1Y -18.7%
PRGO
PRGO • Ireland
Perrigo Company plc
15.06 USD
2.09B USD 1Y -33%
ROVI.MC
ROVI.MC • Spain
LABORATORIOS FARMACEUTICOS ROVI
58.05 EUR
3.33B USD 1Y -1.1%
ALKS
ALKS • Ireland
Alkermes plc
40.61 USD
6.81B USD 1Y +27.3%
HLUN-A.CO
HLUN-A.CO • Denmark
H. Lundbeck A/S A
43.8 DKK
6.51B USD 1Y +21.3%
HLUN-B.CO
HLUN-B.CO • Denmark
H. Lundbeck A/S B
45.96 DKK
6.83B USD 1Y +0.8%
DMP.DE
DMP.DE • Germany
Dermapharm Holding SE I
38.4 EUR
2.13B USD 1Y +15.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
28.3% p.a.
Max Drawdown (5Y)
-51.9%
Sharpe Ratio (5Y)
-0.34
Beta Factor
0.65
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -62.8% in the extended horizon.
ende